TAK 448

Drug Profile

TAK 448

Alternative Names: RVT-602; TAK-448

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Millennium
  • Developer Millennium; Takeda; Takeda Oncology
  • Class Antineoplastics
  • Mechanism of Action KISS1R protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypogonadism
  • Discontinued Prostate cancer

Most Recent Events

  • 08 Dec 2016 Takeda terminates a phase II trial in Hypogonadism (In adults, In the elderly) in USA because the study did not meet the primary endpoints (SC) (NCT02381288)
  • 07 Jun 2016 TAK 448 licensed to Myovant worldwide
  • 01 Sep 2015 Phase-II clinical trials in Hypogonadism (In adults, In the elderly) in USA (SC) (NCT02381288)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top